Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COPD with elevated sputum group 2 innate lymphoid cells is characterized by severe disease

Cameron H. Flayer, Angela L. Linderholm, Moyar Q. Ge, Maya Juarez, Lisa Franzi, Tina Tham, Melissa Teuber, Shu-Yi Liao, Michael Schivo, Brooks Kuhn, Amir Zeki, Angela Haczku
doi: https://doi.org/10.1101/2023.11.21.23298837
Cameron H. Flayer
1Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela L. Linderholm
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moyar Q. Ge
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maya Juarez
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Franzi
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina Tham
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa Teuber
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shu-Yi Liao
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Schivo
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brooks Kuhn
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amir Zeki
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Haczku
2Center for Comparative Respiratory Biology and Medicine, University of California, Davis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: haczku{at}ucdavis.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Rationale Pulmonary innate immune cells play a central role in the initiation and perpetuation of chronic obstructive pulmonary disease (COPD), however the precise mechanisms that orchestrate the development and severity of COPD are poorly understood.

Objectives We hypothesized that the recently described family of innate lymphoid cells (ILCs) play an important role in COPD.

Methods Subjects with COPD and healthy controls were clinically evaluated, and their sputum samples were assessed by flow cytometry. A mouse model of spontaneous COPD [genetically deficient in surfactant protein-D (SP-D-/-)] and ozone (O3) exposure were used to examine the mechanism by which lack of functional SP-D may skew ILC2s to produce IL-17A in combination with IL-5 and IL-13, leading to a mixed inflammatory profile and more severe disease.

Measurements and Main Results COPD was characterized by poor spirometry, sputum inflammation, and the emergence of sputum GATA3+ ILCs (ILC2s), but not T-bet+ ILCs (ILC1s) nor RORγt+ ILCs (ILC3s). COPD subjects with elevated sputum ILC2s (the ILC2high group) had worse spirometry and sputum neutrophilia and eosinophilia than healthy and ILC2low subjects. This was associated with the presence of dual-positive IL-5+IL-17A+ and IL-13+IL-17A+ ILCs and nonfunctional SP-D in the sputum in ILC2high subjects. SP-D-/- mice showed spontaneous airway neutrophilia. Lack of SP-D in the mouse lung licensed ILC2s to produce IL-17A, which was dose-dependently inhibited by recombinant SP-D. SP-D-/- mice showed enhanced susceptibility to O3-induced airway neutrophilia, which was associated with the emergence of inflammatory IL-13+IL-17A+ ILCs.

Conclusions We report that the presence of sputum ILC2s predicts the severity of COPD, and unravel a novel pathway of IL-17A plasticity in lung ILC2s, prevented by the immunomodulatory protein SP-D.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the Tobacco-Related Disease Research Program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of University of California, Davis gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • Figures and associated figure legends have been updated.

Data Availability

All data produced in the present work are available upon reasonable request to the authors.

  • ABBREVIATIONS

    COPD
    Chronic Obstructive Pulmonary Disease
    SP-D
    Surfactant Protein-D
    ILC
    Innate Lymphoid Cell
    ILC1
    Group 1 Innate Lymphoid Cell
    ILC2
    Group 2 Innate Lymphoid Cell
    ILC3
    Group 3 Innate Lymphoid Cell
    FEV1
    Forced Expiratory Volume in one second
    FVC
    Forced Vital Capacity
    GOLD
    Global Initiative for Chronic Obstructive Lung Disease
    PFT
    Pulmonary Function Testing
    mMRC
    Modified Medical Research Council scale
    CAT
    COPD Assessment Test
    MP
    Macrophage/monocyte
    LC
    Lymphocyte
    NP
    Neutrophil
    EP
    Eosinophil
    WT
    C57BL/6 Wild-type
    BAL
    Bronchoalveolar Lavage Fluid
    O3
    Ozone
    PBS
    Phosphate-buffed Saline
    rSP-D
    Mouse Recombinant SP-D
    SpO2
    Specific Oxygen
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted April 03, 2024.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    COPD with elevated sputum group 2 innate lymphoid cells is characterized by severe disease
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    COPD with elevated sputum group 2 innate lymphoid cells is characterized by severe disease
    Cameron H. Flayer, Angela L. Linderholm, Moyar Q. Ge, Maya Juarez, Lisa Franzi, Tina Tham, Melissa Teuber, Shu-Yi Liao, Michael Schivo, Brooks Kuhn, Amir Zeki, Angela Haczku
    medRxiv 2023.11.21.23298837; doi: https://doi.org/10.1101/2023.11.21.23298837
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    COPD with elevated sputum group 2 innate lymphoid cells is characterized by severe disease
    Cameron H. Flayer, Angela L. Linderholm, Moyar Q. Ge, Maya Juarez, Lisa Franzi, Tina Tham, Melissa Teuber, Shu-Yi Liao, Michael Schivo, Brooks Kuhn, Amir Zeki, Angela Haczku
    medRxiv 2023.11.21.23298837; doi: https://doi.org/10.1101/2023.11.21.23298837

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Respiratory Medicine
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)